BGI Reports the Availability of RT-PCR SARS-CoV-2 Test for Clinical Use in the US

 BGI Reports the Availability of RT-PCR SARS-CoV-2 Test for Clinical Use in the US

BGI Reports the Availability of RT-PCR SARS-CoV-2 Test for Clinical Use in the US

Shots:

  • BGI’s Real-Time Fluorescent RT-PCR test is now commercially available in the US for detecting SARS-CoV-2. Following the FDA’s guidance, BGI’s detection kit is eligible to be used instantly to accelerate clinical testing for COVID-19
  • BGI has applied to the US FDA for EUA for its detection kit and has received NMPA’s approval on Jan 26, 2020, followed by CE-IVD marking on Mar 2, 2020.
  • BCI has scaled up manufacturing with a daily capacity of up to 300,000 reactions per day and is distributing its SARS-CoV-2 detection kits to 50+ countries and regions around the globe

Click here to­ read full press release/ article | Ref: BGI | Image: BGI

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post